Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
- 3 January 2020
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (4) , 2752-2763
Abstract
Dysregulated myeloid cell activity underlies a variety of pathologies, including immunosuppression in malignant cancers. Current treatments to alter myeloid cell behavior also alter other immune cell subpopulations and nonimmune cell types with deleterious side effects. Therefore, improved selectivity of myeloid treatment is an urgent need. To meet this need, we demonstrate a novel, targeted nanoparticle system that achieves superior myeloid selectivity both in vitro and in vivo. This system comprises: (1) granulocyte-colony stimulating factor (G-CSF) as a targeting ligand to promote accumulation in myeloid cells, including immunosuppressive myeloid-derived suppressor cells (MDSCs); (2) albumin nanoparticles 100–120 nm in diameter that maintain morphology and drug payload in simulated physiological conditions; and (3) a fluorophore that enables nanoparticle tracking and models a therapeutic molecule. Here, we show that this strategy achieves high myeloid uptake in mixed primary immune cells and that nanoparticles successfully infiltrate the 4T1 triple-negative breast tumor murine microenvironment, where they preferentially accumulate in myeloid cells in a mouse model. Further development will realize diagnostic myeloid cell tracking applications and therapeutic delivery of myeloid-reprogramming drugs.Keywords
Funding Information
- American Association for Cancer Research (17-20-26-SMIT)
- Breast Cancer Research Foundation (17-20-26-SMIT)
This publication has 56 references indexed in Scilit:
- A Review of Indocyanine Green Fluorescent Imaging in SurgeryInternational Journal of Biomedical Imaging, 2012
- Targeted Indocyanine-Green-Loaded Calcium Phosphosilicate Nanoparticles for In Vivo Photodynamic Therapy of LeukemiaACS Nano, 2011
- Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13Cancer Immunology, Immunotherapy, 2011
- Pharmacokinetics and Pharmacodynamics of PegfilgrastimClinical Pharmacokinetics, 2011
- A New Mechanism for Blocking Myeloid-Derived Suppressor Cells by CpGClinical Cancer Research, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2011
- Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasisJournal of Genetics and Genomics, 2010
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse modelsProceedings of the National Academy of Sciences, 2009
- cDNA microarray analysis of the differentially expressed genes involved in murine pre-osteoclast RAW264.7 cells proliferation stimulated by dexamethasoneLife Sciences, 2008
- The Terminology Issue for Myeloid-Derived Suppressor CellsCancer Research, 2007